News | October 26, 2009

Diagnostic Imaging the Key Driver of Personalized Medicine

October 28, 2009 - The imaging industry, especially the new molecular technologies, will drive personalized medicine, in which therapy is designed for the individual patient, according to a report by the market research group Kalorama Information.

If images can reveal not just the heightened metabolic activity characteristic of tumors but the tumors' chemical signatures, physicians can devise individualized therapies, the report says. This would lead to more effective treatments at a lower cost, according to the findings of "Medical Imaging Markets: Contrast Agents," from the Kalorama report.

While medical imaging equipment markets have experienced a slump in sales due to the recession, this is not the case for contrast agents and radiopharmaceuticals. Kalorama expects yearly growth rates for contrast agents used with most modalities to range from 5 to 11 percent. Radiopharmaceuticals, which are radioactive pharmaceuticals used as tracers in the diagnosis and treatment of many illnesses in nuclear medicine and molecular imaging, will experience slightly stronger annual growth - in the range of 10 to 16 percent from $830 million in 2008.

Nuclear medicine, including SPECT and PET, will change how diseases such as cancer or Alzheimer's are treated. Using radiopharmaceuticals, after the illness is identified and treatment begins, doctors can evaluate its effectiveness by tracking the production or inhibition of amyloids, instead of waiting months to evaluate subjectively whether behavior has changed. If a drug does not have the desired effect, treatment can be adjusted.

"Because molecular imaging allows for functional as well as anatomical imaging, diseases can be diagnosed at a much earlier stage and individualized therapies applied," said Bruce Carlson, publisher of Kalorama Information. "With nuclear medicine making gains as a powerful tool for identifying and targeting the root of disease, radiopharmaceutical contrast agents are sure to enjoy strong growth."

Both diagnostic and therapeutic radiopharmaceuticals are becoming increasingly important as the market shifts towards molecular imaging, which is expected to remain at the forefront of research given its unique ability to image molecular abnormalities that are the basis of disease and the processes that are in progress, prior to the structural changes produced by the processes.

For more information: www.kaloramainformation.com

Related Content

PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...
TriHealth in Cincinnati

TriHealth in Cincinnati.

Sponsored Content | Case Study | Contrast Media Injectors | March 06, 2018
The continuing search for advantages to improve workflow has radiology departments constantly searching for new...
Guerbet Presents Contrast&Care Injection Management Solution at ECR 2018
News | Contrast Media | February 28, 2018
February 28, 2018 — Guerbet will present its new Contrast&Care application, as well as other...
Overlay Init